Artivila Therapeutics Wins First Prize at 'Maker China' Shenzhen SME Innovation & Entrepreneurship Competition with AI-Powered Neurodegenerative Drug Program

This achievement not only demonstrates Artivila's profound technical accumulation and innovative strength in the interdisciplinary field of artificial intelligence and biomedicine but also highlights its tremendous potential in addressing the challenges of treating neurodegenerative diseases and nerve injuries. This award is not only a full recognition of the years of dedication by the Artivila team but also reflects the broad application prospects of artificial intelligence technology in the biopharmaceutical field, while setting a model case for the industry in leveraging technology to empower drug development.

ArtivilaTargeted and laid out as early as the initial stage of establishmentIn the AI + pharmaceuticals track, the company firmly believes that advanced AI technology will bring significant changes to the healthcare industry. After years of effort, the company has laid a solid foundation for AI-driven pharmaceuticals. The software and large model products independently developed by the company's team, which leverage AI to empower biopharmaceutical R&D, are now being used to support various stages of the company’s multiple new drug developments: such as using AI for novel drug design, expanding druggable chemical space, optimizing physicochemical properties of drugs, predicting compound toxicity and pharmacokinetic characteristics; building virtual screening platforms for large-scale compound libraries to quickly identify potential active compounds through AI algorithms; constructing cross-species metabolism prediction models to enhance clinical translation of candidate compounds. Based on its AI platform technology, Artivila has...WillMultiple Targeted Small Molecule Innovative DrugsAdvanced to PreclinicalOrClinicalStage, including orally administered small molecule drugs in the field of autoimmune diseases2024Obtained clinical approval in both China and the US in [Year], and has now successfully completed clinical trials.IPhase, the project will be launched in2026Year of Entry2Phase Clinical.

ArtivilaThe Project for This CompetitionFor Chemotherapy-Induced Peripheral Neuropathy (CIPN), Amyotrophic Lateral Sclerosis (ALS, commonly known as Lou Gehrig's disease), and other major neurological diseases with unmet clinical needs. It is an innovative therapeutic drug developed by deeply leveraging AI technology. This drug targets a novel(First-in-class)Global Leading Project，Can be used for treatmentChemotherapy-Induced Peripheral NeuropathyCIPN, DiabetesCaused byPeripheral NeuropathyDPN、Traumatic Brain Injury,Amyotrophic Lateral SclerosisALS (commonly known as Lou Gehrig's disease)Such as a variety of neurodegenerative and nerve injury diseases, with a potential market size reaching tens of billions of US dollars.

About Artivila

Artivila is a company focused on using artificial intelligence (Artivila Biopharma is a biotechnology company empowered by an AI platform to drive innovative pharmaceutical R&D. Its unique data and computation-driven drug discovery platform (AI+HI) integrates artificial intelligence, cloud computing, cheminformatics, bioinformatics, drug design, and the team's extensive industry experience, significantly reducing R&D costs and shortening the development cycle. The company has an integrated Al/CADD R&D system and an international team led by top scientists. Its R&D efforts mainly focus on autoimmune diseases, neurodegenerative diseases, and oncology. Artivila currently has five targeted innovative drugs in its pipeline that have entered preclinical/clinical stages, with over 60 patent applications for Chinese and global inventions filed.

Artivila has cumulatively raised nearly300 million yuan, gaining recognition from numerous biopharmaceutical professional investors and comprehensive funds, providing a solid guarantee for the company's rapid and steady development. The company's research projects and platform technologies have also received recognition and support from multiple parties and have won awards in innovation and entrepreneurship competitions many times, including the Excellent Enterprise Award of China Innovation and Entrepreneurship Competition and "Top 50 Innovative Enterprises in China."、"Longgang Dual Innovation Star" Biomedical Innovation and Entrepreneurship Competition - First Prize、“Shenzhen CityMaker China"And" Specialized and Innovative Enterprises Innovation and Entrepreneurship CompetitionFirst Prizeetc.

Artivila, Diligent and Innovative, Committed to Changing the Fate of Patients Worldwide!